Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Edesa Biotech Inc (EDSA)
Edesa Biotech Inc (EDSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Edesa Biotech to Present at ARDS Drug Development Summit AccessWire - Mon Jul 11, 2022

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan,...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study AccessWire - Tue May 24, 2022

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company...

EDSA : 0.8521 (-0.90%)
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference AccessWire - Thu May 19, 2022

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan,...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results AccessWire - Fri May 13, 2022

TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected AccessWire - Thu Apr 28, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

EDSA : 0.8521 (-0.90%)
Edesa Biotech Appoints Strategy Expert to Board of Directors AccessWire - Tue Mar 29, 2022

TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering AccessWire - Thu Mar 24, 2022

TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AccessWire - Tue Mar 22, 2022

TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study AccessWire - Thu Feb 17, 2022

TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update...

EDSA : 0.8521 (-0.90%)
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results AccessWire - Mon Feb 14, 2022

TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

EDSA : 0.8521 (-0.90%)

Barchart Exclusives

Broadcom Looks Deeply Undervalued Given Its Massive Free Cash Flow Margins Barchart - 14 minutes ago
Broadcom recently released impressive results for its fiscal Q3. The semiconductor company reported a massive 52% FCF margin on revenue. This could push AVGO stock significantly higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot